US investment banking titans Goldman Sachs and JP Morgan have reported much stronger than expected resultsacross much of their businesses for the first-quarter of 2015. That could imply a positive update is imminent from Barclays (LSE: BARC) provided it hasnt cut back its investment bank too far, too fast.
Elsewhere in the market, the Fool’s experts believe sales could treble in just five yearsatthise-commercestealth attack whosemaverick CEO may have been underestimated by the City.For more free information on this daring buy, click here now.
A Bigger Piece Of A 4 Billion Pie?
This fast-growing pharmaceutical business could be all set to become a potential blockbuster.
Recent approvals in Europe and Japan of its latest niche drug means it can now tap a market worth an estimated 4bn a year potentially doubling its sales in the process.
Thats just one of the reasons why our Motley Fool analysts think this under-the-radar innovator could be among the big winners of tomorrow.
To find out more, click here to download this FREE small-cap report now